Sub menu

 

 

Australian Public Assessment Reports (AusPAR)

Search our AusPAR dataset for information on the evaluation of prescription medicines.

An AusPAR provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve an application.

For more information see Australian Public Assessment Reports for prescription medicines (AusPARs).

Use the filters below to narrow your search.

Filter results

You can narrow down the results using the filters.

Filters applied:Clear all
71 result(s) found, displaying 1 to 25

  • AusPAR: Sacituzumab govitecan

    Australian Public Assessment Report (AusPAR)
    New AusPAR for Trodelvy (sacituzumab govitecan) for the treatment of breast cancer.

  • AusPAR: lemborexant

    Australian Public Assessment Report (AusPAR)
    New AusPAR for Dayvigo (lemborexant) for the treatment of insomnia.

  • AusPAR: Rabies immunoglobulin

    Australian Public Assessment Report (AusPAR)
    New AusPAR for KamRAB (rabies immunoglobulin) for the treatment of passive, transient post-exposure prophylaxis of rabies infection.

  • AusPAR: Elasomeran (mRNA-1273)

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Elasomeran (mRNA-1273)

  • AusPAR: Pegvaliase

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Pegvaliase

  • AusPAR: Regdanvimab

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Regdanvimab

  • AusPAR: Adalimumab

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Adalimumab

  • AusPAR: Casirivimab/imdevimab

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Casirivimab/imdevimab

  • AusPAR: BNT162b2 (mRNA)

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for BNT162b2 (mRNA)

  • AusPAR: ChAdOx1-S

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for ChAdOx1-S - COVID-19 Vaccine AstraZeneca

  • AusPAR: Pertuzumab/trastuzumab

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Pertuzumab/trastuzumab

  • AusPAR: Eslicarbazepine acetate

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Eslicarbazepine acetate

  • AusPAR: Fostemsavir trometamol

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Fostemsavir trometamol

  • AusPAR: Sofosbuvir/velpatasvir

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Sofosbuvir/velpatasvir

  • AusPAR: Risdiplam

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Risdiplam

  • AusPAR: Elasomeran

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Elasomeran

  • AusPAR: Upadacitinib

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Upadacitinib

  • AusPAR: Crizanlizumab

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Crizanlizumab

  • AusPAR: Satralizumab

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Satralizumab

Help us improve this page